Levi C, et al. - Researchers in this small case series ascertain mid-term efficacy and safety of the use of eculizumab to prevent or treat atypical hemolytic-uremic syndrome recurrence after kidney transplantation. Findings confirm that eculizumab is highly effective in preventing posttransplantation atypical hemolytic uremic syndrome recurrence, yet may not fully block antibody-mediated rejections pathogenesis.